Transaminases and Hy's law analysis
±, Twenty‐nine
HOFH
Twenty‐nine HoFH patients in the pivotal phase 3 trial (follow‐up ≤1.5 years) were monitored for elevations in transaminases and any possible elevations in bilirubin (Figure Mean aminotransferase and bilirubin levels from the pivotal phase 3 trial in HoFH. Values represent means ± standard deviation. ULN for bilirubin (all patients) is 1.2 mg/dl; ULN for ALT in females is 33 and males is 40 IU/L; ULN for AST in females is 36 and males is 43 IU/L. ALT, alanine aminotransferase; AST, aspartate aminotransferase; ULN, upper limit of normal.In addition, a modest and gradual decrease in mean body weight (from 73.5 ± 18.1 kg at baseline to 67.8 ± 13.0 at week 78; p = .004) was observed (Figure Similarly, among the 214 patients in the FAS of the LOWER registry treated over an 8‐year period with lomitapide 5–40 mg/day (Figure In the 34 Italian patients reported here (genetic status reported in Table 